二尖瓣与主动脉瓣联合手术后的远期结果:修复还是置换?
该多中心回顾性队列纳入1992年至2016年间1122例同期行主动脉瓣与二尖瓣手术的患者,其中837例(74.6%)行二尖瓣修复、285例(25.4%)行二尖瓣置换,风湿性病因占59.4%。倾向性评分匹配(232例)后,二尖瓣置换组30天死亡率在匹配前更高(4.2% vs 1.8%,P=0.021),匹配后差异未达统计学显著(4.7% vs 1.7%,P=0.06);置换组远期生存更低,匹配后及风湿性子组中差异分别未达统计学显著和显著。作者认为二尖瓣修复在多数患者中可行,应作为首选。
要点
- 二尖瓣修复占74.6%,风湿性病因占59.4%,既往二尖瓣干预、风湿性病因等与二尖瓣置换独立相关。
- 二尖瓣置换组30天死亡率4.2% vs 修复组1.8%(P=0.021),匹配后4.7% vs 1.7%(P=0.06)。
- 12年无二尖瓣再手术率修复组94.7±1.1% vs 置换组89.0±3.1%(P=0.004),风湿性亚组中两组相似。
核心结论
- 二尖瓣修复可在多数同期行主动脉瓣置换的患者中实施,作者认为只要可行应作为首选,因其与更低的早期和远期死亡率及非风湿性患者更高的无再手术率相关。
研究设计与样本
- 多中心回顾性队列研究,纳入1992年1月至2016年12月在Coimbra和Santiago两个中心连续接受同期主动脉瓣与二尖瓣手术的1122例患者。
- 其中837例(74.6%)行二尖瓣修复,285例(25.4%)行二尖瓣置换;风湿性病因666例(59.4%)。
- 累积随访9522.6患者年(第25至75百分位2.6至13.2年),95.6%患者随访完整;采用1:1倾向性评分匹配232例比较两种术式。
主要发现
- 既往二尖瓣干预、风湿性病因、慢性阻塞性肺疾病、较高程度的二尖瓣和三尖瓣反流及肺动脉高压与二尖瓣置换独立相关。
- 30天死亡率二尖瓣置换组4.2% vs 修复组1.8%(P=0.021),倾向性评分匹配后为4.7% vs 1.7%(P=0.06)。
- 12年远期生存率二尖瓣置换组53.3±4.5% vs 修复组61.7±2.0%(P=0.026),匹配后为54.6±4.9% vs 63.2±3.8%(P=0.062),风湿性亚组为57.9±4.8% vs 68.0±2.5%(P=0.018)。
- 12年无二尖瓣再手术率修复组94.7±1.1% vs 置换组89.0±3.1%(P=0.004),风湿性二尖瓣疾病患者中两组相似。
关键数值与推荐
- 二尖瓣修复组30天死亡率1.8%,二尖瓣置换组4.2%(P=0.021);匹配后修复组1.7%,置换组4.7%(P=0.06)。
- 12年生存率修复组61.7±2.0%,置换组53.3±4.5%(P=0.026);匹配后修复组63.2±3.8%,置换组54.6±4.9%(P=0.062);风湿性亚组修复组68.0±2.5%,置换组57.9±4.8%(P=0.018)。
- 12年无二尖瓣再手术率修复组94.7±1.1%,置换组89.0±3.1%(P=0.004)。
临床怎么用
- 作者认为二尖瓣修复在多数同期行主动脉瓣置换的患者中可行,只要可行应作为首选术式。
- 作者认为二尖瓣修复与更低的早期和远期死亡率及非风湿性患者更高的无再手术率相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The reported superiority of mitral valve (MV) repair for isolated MV regurgitation has not been confirmed in mitroaortic valve surgery. Our goals were to evaluate the feasibility of repair in patients undergoing mitral and aortic valve surgery and to identify factors predisposing to MV replacement, to compare long-term outcomes (survival and MV reoperation) of repair and replacement and to perform a subgroup analysis in patients with rheumatic MV disease. METHODS: From January 1992 through December 2016, 1122 consecutive patients were submitted to concomitant aortic and MV surgery in 2 different centres (Coimbra and Santiago). Of these, 837 patients underwent MV repair (74.6%) and 285 patients had MV replacement (25.4%). Rheumatic aetiology was predominant (666 patients; 59.4%). Cumulative follow-up was 9522.6 patient-years (25th-75th percentile 2.6-13.2 years) and was complete for 95.6% of patients. Propensity score matching (1:1) was performed in 232 patients for comparing each treatment option (MV repair and MV replacement). RESULTS: Previous MV intervention, rheumatic aetiology, chronic obstructive pulmonary disease, higher degrees of tricuspid and mitral regurgitation and pulmonary hypertension were independently correlated with MV replacement. The 30-day mortality rate was higher in patients with MV replacement (4.2% vs 1.8%, P = 0.021) and was confirmed in the propensity score matching (4.7% vs 1.7%, P = 0.06). Late survival was lower in the MV replacement group (53.3 ± 4.5% vs 61.7 ± 2.0% at 12 years; P = 0.026) and was confirmed in the propensity score matching (54.6 ± 4.9% vs 63.2 ± 3.8%, P = 0.062) and rheumatic subgroup (57.9 ± 4.8% vs 68.0 ± 2.5%, P = 0.018). Freedom from MV reoperation at 12 years was higher in the MV repair group (94.7 ± 1.1% vs 89.0 ± 3.1%, P = 0.004) but similar in patients with rheumatic MV disease. CONCLUSIONS: MV repair can be performed in most patients undergoing aortic valve replacement. It should be the procedure of choice whenever feasible, because it is associated with lower early and late mortality rates and with freedom from reoperation in non-rheumatic patients.
引用
- Coutinho GF, Martínez Cereijo JM, Correia PM, et al. Long-term results after concomitant mitral and aortic valve surgery: repair or replacement? Eur J Cardiothorac Surg. 2018. PMID: 29800093. doi:10.1093/ejcts/ezy205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。